BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol 2016; 22(6): 2118-2125 [PMID: 26877616 DOI: 10.3748/wjg.v22.i6.2118]
URL: https://www.wjgnet.com/1007-9327/full/v22/i6/2118.htm
Number Citing Articles
L. M. Tchoumba Tchoumi, M. L. Nchouwet, S. L. Poualeu Kamani, W. Yousseu Nana, R. C. Douho Djimeli, A. Kamanyi, S. L. Wansi Ngnokam. Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar ratsAdvances in Traditional Medicine 2021; 21(3): 485 doi: 10.1007/s13596-020-00470-6
Lehar Khanna, Thorvardur R. Halfdanarson, Mohamad B. Sonbol, Rachel Eiring, Teresa Prond, Michael Camilleri. Bile Acid Malabsorption in Patients with Neuroendocrine TumorsDigestive Diseases and Sciences 2022; 67(6): 2517 doi: 10.1007/s10620-021-07189-7
V. N. Joish, F. Frech, P. Lapuerta. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogsJournal of Medical Economics 2018; 21(2): 182 doi: 10.1080/13696998.2017.1387120
Arvind Dasari, Vijay N. Joish, Raul Perez-Olle, Sam Dharba, Kavitha Balaji, Daniel M. Halperin. Work productivity burden and indirect costs associated with carcinoid syndrome diarrheaExpert Review of Pharmacoeconomics & Outcomes Research 2020; 20(5): 507 doi: 10.1080/14737167.2019.1660646
M.E. Pavel, E. Baudin, K.E. Öberg, J.D. Hainsworth, M. Voi, N. Rouyrre, M. Peeters, D.J. Gross, J.C. Yao. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 studyAnnals of Oncology 2017; 28(7): 1569 doi: 10.1093/annonc/mdx193
Julie Hallet, C. H. L. Law, M. Cheung, N. Mittmann, N. Liu, H. D. Fischer, S. Singh. Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based AnalysisAnnals of Surgical Oncology 2017; 24(11): 3312 doi: 10.1245/s10434-017-5986-0
Tanya Burton, Pablo Lapuerta. Economic analysis of inadequate symptom control in carcinoid syndrome in the United StatesFuture Oncology 2018; 14(23): 2361 doi: 10.2217/fon-2018-0129
Matthew H Kulke, Hagen F Kennecke, Kris Murali, Vijay N Joish. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World StudyCancer Management and Research 2021; : 7439 doi: 10.2147/CMAR.S330429
Boris G. Naraev, Magnus Halland, Daniel M. Halperin, Amy J. Purvis, Thomas M. O'Dorisio, Thorvardur R. Halfdanarson. Management of Diarrhea in Patients With Carcinoid SyndromePancreas 2019; 48(8): 961 doi: 10.1097/MPA.0000000000001384
Arvind Dasari, Vijay N Joish, Raul Perez-Olle, Samyukta Dharba, Kavitha Balaji, Daniel M Halperin. Direct costs of carcinoid syndrome diarrhea among adults in the United StatesWorld Journal of Gastroenterology 2019; 25(47): 6857-6865 doi: 10.3748/wjg.v25.i47.6857
Jonathan Strosberg, Vijay N. Joish, Susan Giacalone, Raul Perez-Olle, Ann Fish-Steagall, Kanika Kapoor, Sam Dharba, Pablo Lapuerta, Al B. Benson. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real WorldThe Oncologist 2019; 24(11): 1446 doi: 10.1634/theoncologist.2018-0921
Al B. Benson, Jonathan Strosberg, Vijay N. Joish, Samyukta Dharba, Dipa Sapre, Pablo Lapuerta. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement FrequencyPancreas 2020; 49(3): 408 doi: 10.1097/MPA.0000000000001496
Lynn Huynh, Todor Totev, Francis Vekeman, Maureen P. Neary, Mei S. Duh, Al B. Benson. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LARJournal of Medical Economics 2017; 20(9): 945 doi: 10.1080/13696998.2017.1337019
Lowell B. Anthony, Thomas M. O'Dorisio. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key IssuesThe Oncologist 2021; 26(7): e1171 doi: 10.1002/onco.13847
I-Wen Pan, Daniel M. Halperin, Bumyang Kim, James C. Yao, Ya-Chen Tina Shih. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid SyndromePharmacoEconomics 2021; 39(11): 1271 doi: 10.1007/s40273-021-01071-0
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen. Carcinoid-syndromeCurrent Opinion in Endocrinology & Diabetes and Obesity 2018; 25(1): 22 doi: 10.1097/MED.0000000000000376
Enrique Grande, Ángel Díaz, Carlos López, Javier Munarriz, Juan-José Reina, Ruth Vera, Beatriz Bernárdez, Javier Aller, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez Fonseca, Marta Trapero-Bertran. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic reviewTherapeutic Advances in Endocrinology and Metabolism 2019; 10: 204201881982821 doi: 10.1177/2042018819828217
Louisa G. Gordon, Thomas M. Elliott, Kate Wakelin, Simone Leyden, John Leyden, Michael Michael, Nick Pavlakis, Jan Mumford, Eva Segelov, David K. Wyld. The Economic Impact on Australian Patients with Neuroendocrine TumoursThe Patient - Patient-Centered Outcomes Research 2020; 13(3): 363 doi: 10.1007/s40271-020-00412-z
Michel Archange Fokam Tagne, Paul Aimé Noubissi, Gaëtan Olivier Fankem, René Kamgang. Effects of Oxalis barrelieri L. (Oxalidaceae) aqueous extract on diarrhea induced by Shigella dysenteriae type 1 in ratsHealth Science Reports 2018; 1(2): e20 doi: 10.1002/hsr2.20
Joseph S Dillon, Chandrikha Chandrasekharan. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrheaFuture Oncology 2018; 14(12): 1155 doi: 10.2217/fon-2017-0340
Vijay N. Joish, Feride Frech, Pablo Lapuerta. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan PerspectiveClinical Therapeutics 2017; 39(12): 2338 doi: 10.1016/j.clinthera.2017.10.019
A. Custodio, P. Jimenez-Fonseca, A. Carmona-Bayonas, M. J. Gomez, M. I. Del Olmo-García, I. Lorenzo, J. Á. Díaz, N. Canal, G. De la Cruz, C. Villabona. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY studyClinical and Translational Oncology 2021; 23(10): 2046 doi: 10.1007/s12094-021-02608-7
Kira Oleinikov, Shani Avniel-Polak, David J. Gross, Simona Grozinsky-Glasberg. Carcinoid Syndrome: Updates and Review of Current TherapyCurrent Treatment Options in Oncology 2019; 20(9) doi: 10.1007/s11864-019-0671-0
Kelly Fust, Michael Maschio, Michele Kohli, Simron Singh, D. Mark Pritchard, Florence Marteau, Peter Myrenfors, Marion Feuilly. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid SyndromePharmacoEconomics 2020; 38(6): 607 doi: 10.1007/s40273-020-00896-5
Dieter Hörsch, Lowell Anthony, David J. Gross, Juan W. Valle, Staffan Welin, Marta Benavent, Martyn Caplin, Marianne Pavel, Emily Bergsland, Kjell Öberg, Kenneth B. Kassler-Taub, Polina Binder, Phillip Banks, Pablo Lapuerta, Matthew H. Kulke. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH StudyNeuroendocrinology 2022; 112(3): 298 doi: 10.1159/000516958